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http://www.biomedcentral.com/1471-2156/15/42RESEARCH ARTICLE Open AccessDetermining immune components necessary for
progression of pigment dispersing disease to
glaucoma in DBA/2J mice
K Saidas Nair1,2, Jessica Barbay1, Richard S Smith1, Sharmila Masli3 and Simon WM John1,4*Abstract
Background: The molecular mechanisms causing pigment dispersion syndrome (PDS) and the pathway(s) by
which it progresses to pigmentary glaucoma are not known. Mutations in two melanosomal protein genes (Tyrp1b
and GpnmbR150X) are responsible for pigment dispersing iris disease, which progresses to intraocular pressure (IOP)
elevation and subsequent glaucoma in DBA/2J mice. Melanosomal defects along with ocular immune abnormalities
play a role in the propagation of pigment dispersion and progression to IOP elevation. Here, we tested the role of
specific immune components in the progression of the iris disease and high IOP.
Results: We tested the role of NK cells in disease etiology by genetically modifying the B6.D2-GpnmbR150X Tyrp1b
strain, which develops the same iris disease as DBA/2J mice. Our findings demonstrate that neither diminishing NK
mediated cytotoxic activity (Prf1 mutation) nor NK cell depletion (Il2rg mutation) has any influence on the severity
or timing of GpnmbR150X Tyrp1b mediated iris disease. Since DBA/2J mice are deficient in CD94, an important
immune modulator that often acts as an immune suppressor, we generated DBA/2J mice sufficient in CD94.
Sufficiency of CD94 failed to alter either the iris disease or the subsequent IOP elevation. Additionally CD94 status
had no detected effect on glaucomatous optic nerve damage.
Conclusion: Our previous data implicate immune components in the manifestation of pigment dispersion and/or
IOP elevation in DBA/2J mice. The current study eliminates important immune components, specifically NK cells
and CD94 deficiency, as critical in the progression of iris disease and glaucoma. This narrows the field of possible
immune components responsible for disease progression.
Keywords: Glaucoma, Pigmentary glaucoma, Mouse model, DBA/2J, CD94, NK cells, ACAID, Iris disease,
Intraocular pressureBackground
Glaucoma is a group of diseases in which retinal gan-
glion cell death and optic nerve degeneration lead to
blindness. High intraocular pressure (IOP) is a major
risk factor contributing to glaucoma [1]. Pigment disper-
sion syndrome (PDS) is a common condition that results
in the dispersion of iris pigment into the anterior cham-
ber (AC) [2,3]. The dispersed pigment accumulates
within the ocular drainage structures, resulting in IOP
elevation and glaucoma in some but not all individuals
with PDS [4-8]. The molecular mechanisms causing PDS* Correspondence: simon.john@jax.org
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unless otherwise stated.and the pathway(s) by which it progresses to pigmentary
glaucoma are not known.
DBA/2J (D2) mice provide a model of inherited glau-
coma. They develop a pigmentary form of glaucoma
characterized by a pigment-dispersing iris disease, in-
creased IOP, and optic nerve degeneration [9-12]. Muta-
tions in two D2 genes [tyrosinase-related protein 1,
Tyrp1, and glycoprotein (transmembrane) nmb, Gpnmb]
induce the depigmenting iris disease [13,14]. Although
more severe than in most human patients, components
of the D2 phenotype have strong similarities to human
PDS. The Gpnmb mutation induces prominent pigment
dispersion (PD) with a radial slit-like pattern of transillu-
mination defects and atrophy of the iris pigment epithe-
lium, all of which are hallmarks of human PDS [14].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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that is present in multiple cell types with lysosomal-
related organelles, including iris cells, dendritic cells, mac-
rophages, NK cells and T cells [15-17]. The Tyrp1 gene
encodes a melanosomal protein with both enzymatic and
structural functions [18-20]. Normally, melanosomes se-
quester cytotoxic intermediates produced during melanin
production. GPNMB and TYRP1 are both transmembrane
melanosomal proteins and their mutations result in leak-
age of the cytotoxic intermediates from melanosomes,
thus leading to degeneration of iris cells and dispersion of
pigment [14].
In addition to the iris, the presence of a mutant allele
of Gpnmb in bone-marrow derived cell lineages is neces-
sary for propagation of the iris disease and the subsequent
elevation of IOP in D2 eyes [21,22]. Since most immune
cells are bone marrow derived, these data suggested a role
of immune cell dysfunction in D2 glaucoma. Although D2
eyes lack clinical signs of obvious inflammation (redeye
and flare), they do exhibit a chronic and mild form of
inflammation characterized by loss of ocular immune priv-
ilege. Both innate and adaptive immune privilege are com-
promised in D2 eyes [21], and immune processes drive the
propagation of the iris disease and overall level of iris de-
pigmentation [21]. Given that melanosomal proteins are
themselves immunogenic [23], it is possible that dispersed
pigment may initiate immune activation to directly inflict
an inflammatory attack on the iris. Thus, melanosomal
defects and the immune system may synergize to cause
severe iris depigmentation and atrophy. Deficiency of
T and B cells (adaptive immune cells) had no affect on
Tyrp1b GpnmbR150X driven iris disease, suggesting that
components of innate immunity contribute to the iris
disease [22]. NK cells are an integral component of
innate immunity. NK cells are implicated in loss of self-
tolerance and can induce disease by directly inflicting
a cytotoxic response against self-tissues. By virtue of
their role in supporting inflammatory responses, NK
cells have been postulated to participate in the patho-
genesis of human diseases such as arthritis and mul-
tiple sclerosis [24].
DBA/2J mice are deficient in CD94, a molecule pri-
marily expressed in NK cells and a small subset of CD8
T cells [25]. CD94 can function both as a suppressor or
activator of immune responses. A recent study suggests
that lack of an immunosupressive function mediated by
CD94 may contribute to the disrupted ocular immune
privilege and progression of D2 glaucoma [26]. CD94 is
present on the cell surface as a homodimer or as a het-
erodimer associated with various NKG2 natural killer
cell receptor family isoforms. The differential activity of
CD94 as an immune activator or as an immune suppres-
sor is dependent on which isoform of NKG2 serves as its
interacting partner [27]. The ligation of CD94/NKG2Areceptors aids in suppression of inflammatory responses
[27,28]. The ligand for CD94/NKG2 is HLA-E in human
and its homolog Qa1 in mouse, which are both nonclas-
sical class I molecules [29,30]. The anti-inflammatory
function of CD94 together with its deficiency in D2
mice makes it an attractive candidate to modulate the
pathogenesis of the depigmenting iris disease and/or
the subsequent glaucoma.
Here, we have tested if Tyrp1b GpnmbR150X driven iris
disease is dependent on NK cell functions. Additionally,
we tested if CD94 deficiency participates in the patho-
genesis of distinct stages of D2 glaucoma. Identification
of the molecular mechanisms causing pigment disper-
sion and the pathway(s) by which it progresses to pig-
mentary glaucoma is crucial for pinpointing processes
that can be targeted by treatments to prevent glaucoma
progression.
Results
Debilitating NK cell function does not alter iris disease
Existing data strongly implicates innate immunity in the
progression of iris disease and subsequent IOP elevation
that occurs in D2 eyes. Because NK cells are an important
component of the innate immune system, we assessed if
altered NK cell activity participates in the propagation of
Tyrp1b GpnmbR150X driven iris disease. To test the role of
NK cells in promoting pigment dispersing iris disease,
we introduced mutations that diminish NK cell function
into the B6.D2-GpnmbR150X Tyrp1b strain. The B6.D2-
GpnmbR150X Tyrp1b strain consists of C57BL/6J mice
that are congenic for the D2 GpnmbR150X and Tyrp1b mu-
tations. This strain develops a pigment dispersing iris dis-
ease with near identical features to that of D2 mice but is
resistant to IOP elevation [31]. Since many immune muta-
tions are available on the C57BL/6J strain background, this
strain is valuable for determining the roles of specific im-
mune processes in the pigment dispersing iris disease.
CD94 is intact in this strain. Thus, it allows any effects of
introduced mutations on NK cells and the iris disease to
be tested without any confounding influence of insuffi-
ciency of CD94. We have introduced two mutations that
influence NK cells into the B6.D2-GpnmbR150X Tyrp1b
strain. We have tested the effects of being homozygous
null for perforin (Prf1−/−) or homozygous null for IL2 re-
ceptor gamma (Il2rg−/−). Prf1−/− mice have suppressed
NK cell mediated cytotoxic function [32], and Il2rg−/−
mice are deficient in NK cells [33]. The Il2rg−/− mice also
lack mature T and B cells [33]. We have previously shown
that that lack T and B cells does not alter the iris disease
by using a Rag1 mutation [22]. Therefore, any observed
alteration of iris disease in Il2rg−/− mice would most likely
reflect NK cell involvement. Neither the Prf1 or Il2rg
mutations had any influence on the iris disease, which was
indistinguishable from that of their wild-type littermates
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tivity nor depletion of NK cells alters the onset or severity
of iris disease, suggesting that NK cells do not mediate this
phenotype.Figure 1 Loss of NK cell activity has no influence on DBA/2J iris disea
of phenotypes at each age was indistinguishable between genotypes. The
Prf1+/+ mice (A-H) at the indicated ages, and the bottom two panels of ey
panel shows broad beam illumination to assess the presence of dispersed
(A-D and I-L). The bottom rows of each panel shows transillumination (E-H
as areas within the image where reflected light passes through the iris. The
similar to that in wild-type mice: eyes of young perforin mutant mice have
characterized by swelling of the peripupillary region (J). At 9 mo, the perip
At 12 mo, there is an increasing degree of iris atrophy including distinct iriCD94 sufficiency fails to rescue the ability of antigen
presenting cells (APC) to support ACAID
The CD94/NKG2A receptor is critical for induction and
immunosupression by CD8 regulatory T cells (Treg) inse. Despite some variability from eye to eye, the range and prevalence
top two panels are representative eyes of B6.D2-Tyrp1bGpnmbR150X
es of B6.D2-Tyrp1b GpnmbR150X Prf1−/− mice (I-P). The top rows of each
pigment within the anterior chamber and iris stromal morphology
and M-P). This assays the degree of iris depigmentation, detectable
onset and progression of iris disease in the perforin mutants are
healthy irides (I,M). At 6 mo, mutant mice exhibit mild iris disease
upillary region becomes atrophic, transillumination is prominent (K,O).
s holes, profound transillumination and pigment dispersion (L,P).
Figure 2 Reduced NK cell number has no influence on Tyrp1bGpnmbR150X mediated iris disease. Despite some variability from eye to eye,
the range and prevalence of phenotypes at each age was indistinguishable between genotypes. The first row for the indicated genotype shows
broad beam illumination to assess the dispersed pigment phenotype and the iris stromal morphology. The second row shows transillumination
patterns assaying for the degree of iris depigmentation. The onset and progression of iris disease in B6.D2-GpnmbR150X Tyrp1b Il2rg−/− (I to P) is
similar to that in B6.D2-GpnmbR150X Tyrp1b Il2rg+/+ mice (A-H). Eyes of young B6.D2-GpnmbR150X Tyrp1b Il2rg−/− mice exhibit healthy irides (I,M). At
6 mo, mutant mice exhibit characteristic swelling of the peripupillary region (J). At 9 mo the iris becomes atrophic, a transillumination defect is
visible, and prominent dispersed pigment is visualized (K,O). At 12 mo, the degree of iris atrophy is prominent as visualized by presence of
distinct iris holes and severe transillumination and pigment dispersion (L,P).
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[26]. A key component of ocular immune privilege,
ACAID, is a form of immune tolerance guided by mul-
tiple afferent and efferent cells [34]. This immune devi-
ation is initiated by F4/80+ ocular APCs that captureantigens in the eye and migrate via the blood to the
spleen. At that site, these APCs generate a population of
Tregs capable of inhibiting Th1-mediated inflammatory
immune responses such as a delayed type hyper-reactivity
(DTH). It has been suggested that antigen presentation by
Figure 3 Flowcytometric assessment of CD94 expression.
Comparison of CD94/NKG2 expressing cells on peripheral blood
mononuclear cell (PBMC) from D2 Klrd1+/+and D2 Klrd1−/− mice (the
Klrd1 gene encodes CD94). A subset of the lymphocytes from D2
Klrd1+/+ mice express the CD94/NKG2 receptor complex (within the
drawn area). In contrast cells from D2 Klrd1−/− did not express the receptor
complex. The data is representative of three independent experiments.
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APCs and its interaction with CD94/NKG2A receptor on
CD8+ Treg T cells is important in the induction of ACAID
[26]. The deficiency of CD94 disrupts CD8 Treg induction
by Qa-1b expressing APCs from the D2 eyes with a conse-
quential loss of ACAID.
Additionally, we previously reported that an inherent
defect in APCs from D2 mice leads to an inability to
support ACAID, which may contribute to disrupted ocu-
lar immune privilege and the progression of glaucoma
[22]. Subsequently, it was demonstrated that D2 mice re-
ceiving intracameral antigen have a reduced frequency
of Qa-1b (CD94 ligand) expressing cells in the iris and
among the F4/80+ APCs in the spleen compared to a
haplotype matched DBA/2NCr strain that is sufficient in
CD94 [26]. Thus, a decrease in Qa-1b restricted antigen
presentation by APCs is likely to impede generation of
immunosuppressive CD8 Tregs and may underlie failure
of D2 APCs to support ACAID. We hypothesize that
CD94 plays a key role in the maintenance of ocular im-
mune privilege and its absence contributes to progres-
sion of glaucoma in D2 eyes.
To test the role of the CD94/NKG2A- Qa-1b axis in ocu-
lar immune regulation and glaucoma progression, we gen-
erated D2 mice that are sufficient in CD94 (D2 Klrd1+/+).
The wild-type CD94 (Klrd1) allele was backcrossed into
present day D2 mice from the DBA/2 J-Dtnbp1sdy/J strain,
which has the ancestral wild-type Klrd1 allele that was
lost from modern D2 mice (see Methods). D2 Klrd+/−
mice were intercrossed to produce Klrd1+/+, Klrd1+/−,
and Klrd1−/− littermates. We assessed expression of CD94
by labeling peripheral blood mononuclear cells with
anti-CD94 and anti-NKG2 antibodies. Flow cytometric
analysis demonstrates coexpression of CD94 and NKG2 in
a subset of lymphocytes from D2 Klrd1+/+ mice but not
D2 Klrd1−/− mice (Figure 3).
First, we determine if CD94 deficiency related changes
in D2 APCs reflect a qualitative defect in their ability to
induce ACAID. Non-ocular APCs, such as F4/80+ mac-
rophages derived from thioglycollate-elicited peritoneal
exudate cells, can be converted into APCs that induce im-
mune deviation similar to that induced by ocular APCs.
This is accomplished by exposing non-ocular APCs to
TGFβ2 in culture. The resulting TGFβ2-exposed per-
ipheral APCs resemble ocular APCs in their functional
phenotype [22]. We compared the ability of TGFβ2
treated APCs derived from D2 mice that are either suffi-
cient or deficient in CD94, to induce immune deviation
by injecting them into recipient mice and thereafter
assessing for inhibition of a DTH response. All experi-
ments utilized genetically identical F1 mice from a cross
between C57BL/6J and DBA/2J (B6D2F1) as recipients.
It is important to note that the use of B6D2F1 recipient
mice ensured expression of wild-type CD94 (Klrd1+/−)by host tissues. Thus, any observed differences are a direct
consequence of an affect of CD94 genotype on ability of
APCs to support ACAID. TGFβ2-treated APCs from con-
trol B6 mice successfully induced immune deviation that
led to inhibition of DTH (Figure 4A). In contrast, APCs
derived from either D2 Klrd1−/− or D2 Klrd1+/+ mice both
failed to inhibit DTH (Figure 4). Thus, irrespective of
CD94 genotype, APCs derived from DBA/2J mice failed to
induce ACAID. These results suggest that another inher-
ent defect(s) in APCs (independent of CD94 or possibly
acting with CD94) contributes to loss of ACAID and
therefore immune privilege in DBA/2J mice.
CD94 sufficiency does not impact the progression to high
IOP and glaucoma
We tested the effect of CD94 sufficiency on the disease
progression to glaucoma. D2 mice of all three genotypes
(Klrd1+/+, Klrd1+/−, and Klrd1−/−) were aged and assessed.
CD94 sufficiency has no affect on the age of onset, pro-
gression, or severity of pigment dispersing iris disease
(Figure 5). We next assessed whether the CD94 sufficiency
alters IOP in D2 mice. Mice of all three genotypes were
aged and their IOP determined. The IOP elevation in
DBA/2J mice peaks from 9 to 12 mo of age, with the IOP
distribution clearly shifting upward between 8 and 9 mo.
We monitored IOP at key ages (9, 10.5, and 12 mo). Our
data demonstrate that IOPs of all three genotypes were
not significantly different at the recorded ages (Figure 6 A,
B). Our results indicate that CD94 sufficiency did not alter
the high IOP phenotype exhibited by D2 mice. Thus, the
CD94 deficiency of modern DBA/2J mice does not influ-
ence either the iris disease or IOP elevation.
Autoimmune mechanisms have been suggested to con-
tribute to retinal ganglion cell death in glaucoma. Immune
mediated damage to the optic nerve has been hypothe-
sized to result from responses elicited against a sensitizing
Figure 4 Tolerogenic capacities of APCs from D2 Klrd1+/+ mice. APCs isolated from mice of the indicated genotypes were injected into
B6D2F1/J recipients. The APCs were first cultured either in absence (Untreated) or presence of TGFβ2 and pulsed with OVA. The ability of the
APCs to induce immune deviation was determined by measuring the ear swelling response of F1 recipients to an OVA challenge (F1s had been
previously inoculated with OVA). Functional immune deviation will result in suppression of a DTH response to the OVA challenge, resulting in no
or minimum ear swelling. In contrast and if APCs are unable to manifest immune deviation, OVA challenge will induce ear swelling. Induction
of immune deviation is detected as the suppression of ear swelling response in the TGFβ2-treated groups as compared to the untreated group.
Ear swelling responses are presented as mean ± SEM. Negative controls (Neg control) were naïve and only received the intrapinnae challenge
injection of OVA.
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though not clearly defined, there is evidence to support in-
volvement of both innate and adaptive immune responses
in glaucomatous neuropathy [35]. In D2 mice, severe
glaucomatous damage is detectable in about 70% of 12-
month-old mice, at this stage the degree of glaucomatous
damage almost reaches saturation, with little damage oc-
curring at older ages [11]. The frequency and nature of
glaucomatous nerve damage was similar between D2 mice
deficient and sufficient in CD94 (Figure 7A, B). Thus,
CD94 deficiency does not alter the ultimate incidence and
severity of optic nerve degeneration.
Discussion
D2 mice develop a form of pigmentary glaucoma involv-
ing a pigment dispersing iris disease, increased IOP, and
degeneration of retinal ganglion cells. Our earlier studies
suggest that melanosomal defects along with ocular im-
mune abnormalities participate in the progression to D2
glaucoma. Here, we demonstrate that innate immune
processes mediated through NK cells are not important
for the progression of the iris disease. In addition, we
rule out natural deficiency of CD94 as a pathogenic fac-
tor necessary for progression of distinct disease stages
that underlie D2 glaucoma.
Innate immune components other that NK cells are
involved in propagation of the iris disease
We have previously reported that reconstitution of irra-
diated D2 mice with B6D2F1 bone marrow rescues theprominent pigment dispersion phenotype that is caused
by mutations in Tyrp1 and Gpnmb [21]. This rescue is
mediated through suppression of ocular immune abnor-
malities detectable early in the disease. Subsequently, we
have identified the Gpnmb gene as an important factor
that mediates this bone marrow derived rescue of this
phenotype [22]. Based on this, we had speculated that a
bone marrow derived lineage that would normally ex-
press Gpnmb reacts abnormally to the iris debris in D2
mice. As a consequence of GPNMB deficiency, the bone
marrow derived cells may either fail to inhibit an ocular
inflammation or may directly inflict an inflammatory at-
tack on the iris, causing severe pigment dispersion and
iris atrophy. We have previously ruled out components
of adaptive immunity (T and B cells) as necessary in the
propagation of Tyrp1 and Gpnmb induced iris disease
[22]. Therefore, these phenotypes are likely dependent
on cell types regulating innate immune responses. Here,
we demonstrate that deficiency of NK cells - an import-
ant component of innate immunity - had no affect on
the propagation of the iris disease.
Other mediators of innate immune responses, includ-
ing macrophages and dendritic cells, express GPNMB
[17]. Importantly, GPNMB acts as a negative regulator
of macrophage mediated inflammatory responses [17].
Macrophages are normally resident in the anterior cham-
ber of the eye and large numbers of pigment-containing
macrophages are visible in the anterior chamber of aged
D2 eyes. As a consequence of the Gpnmb mutation, D2
macrophages may acquire a proinflammatory function
Figure 5 CD94 status does not affect the iris disease in D2 mice. Representative images for mice of each genotype are shown, with broad
beam illumination on top of transillumination images. Comparative analysis of CD94 sufficient and deficient mice (Klrd1+/+and Klrd1−/−) indicates
that the onset and progression of iris disease in D2 Klrd1-/- (A-H) is similar to that in D2 Klrd1+/+ (I-P).
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understanding the role of macrophages in the progression
of the D2 iris disease.
Deficiency of CD94 does not contribute to progression to
D2 glaucoma
Our earlier study has suggested that the inability of D2
mice to support ACAID, a form of ocular immune toler-
ance, may contribute to both the immune dysfunctionand glaucoma progression that occurs in D2 eyes [21]. A
recent report has shown a causal relationship between
CD94/NKG2A receptor and its ability to support ACAID
[26]. Ligation of CD94/NKG2A expressed on a subset of
CD8 Tregs is critical for induction and immunosupression
in ACAID [26,36]. This implies that failure of D2 mice to
support ACAID is partly due to deficiency of CD94 [26].
Ocular APCs are thought to be the primary initiator of
the ACAID response. They act by capturing antigen in
Figure 6 CD94 sufficiency does not alter IOP in D2 mice. In (A)
the data is represented as a scatter plot, and in (B) as bar graphs of
the mean IOP ± SEM (>30 mice). All groups contained at least 30
mice and included both males and females in similar proportions.
Comparative analyses between the three genotypes showed that
there were no significant differences in IOP (P > 0.05 for ages at 9
and 10 mo). At 12 mo time-point, only D2 Klrd1+/− exhibited a
slightly higher mean IOP (P = 0.046). Since IOP values between CD94
sufficient (D2 Klrd1+/+) and deficient (D2 Klrd1+/+) mice are comparable,
this effect is unlikely to be dependent on genotype. A significant
proportion of D2 mice typically show a drop in IOP at around 12
mo of age. The slight increase in mean IOP exhibited by D2 Klrd1+/−
mice is likely due to a high variability in IOP values as a consequence
of their crashing in some mice. Age related ciliary-body atrophy is
though to contribute to this IOP drop at around 12 mo in D2 mice.
Figure 7 Degree of optic nerve degeneration is comparable
between CD94 sufficient and deficient mice. To assess the effects
of CD94 sufficiency on optic nerve degeneration, we analyzed
PPD-stained optic nerve cross sections. For this analysis, CD94
sufficient mice had either a D2 Klrd1+/+ or D2 Klrd1+/− genotype,
while CD94 deficient mice were Klrd1−/−. A) Distributions of optic
nerve damage at 12 mo. B) Representative images from nerves
with no glaucoma have a clear axoplasm and darkly stained myelin
sheath. Nerves with severe damage have extensive axon loss and glial
scarring. CD94 status did not alter glaucomatous optic nerve damage.
For each group > 30 eyes were evaluated.
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poorly understood, complex series of cellular processes
involving interplay of multiple immune cell types includ-
ing B cells and CD8 Tregs [34,37]. We have previously
reported that APCs isolated from D2 mice fail to sup-
port ACAID. This is in agreement with another study
that suggest defects in multiple immune cell-types con-
tribute to a faulty D2 ACAID response [26]. Here, we
demonstrate that the APCs derived from CD94 sufficient
DBA/2J mice continue to exhibit an inherent defect and
fail to support ACAID. Insight into factors controlling
the multiplicity of defects in different immune cell types
Nair et al. BMC Genetics 2014, 15:42 Page 9 of 11
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anism controlling ACAID and ocular immune privilege.
Similarly, a correction of CD94 deficiency alone did
not alter the iris disease, high IOP or degree of optic
nerve degeneration exhibited by D2 mice. The etiology
of IOP elevation and glaucoma in D2 mice is clearly
complex, involving multiple factors. Although mutations
in Gpnmb and Tyrp1 are sufficient to cause iris disease,
our previous work indicates that additional D2 specific
alleles at other loci are needed for progression to high
IOP and glaucoma [31]. Here, we have ruled out CD94
deficiency as a factor necessary for iris disease or pro-
gression to high IOP and glaucoma in D2 mice. Efforts
are underway to identify the additional genes that are
necessary for high IOP and to characterize their role in
the progression from pigment dispersion to IOP eleva-
tion and glaucoma.
Conclusions
Here, we have demonstrated that NK cells are not neces-
sary for the progression of Tyrp1b GpnmbR150X driven
iris disease. In addition, we rule out CD94 deficiency as an
important factor contributing to pathogenesis of D2 glau-
coma. Future studies will attempt to identify immune-
related susceptibility factors that control D2 glaucoma.
Characterizing the genes and mechanisms that underlie
this progression will identify new pathways that can be
evaluated in human pigmentary glaucoma, and may pro-
vide valuable therapeutic targets.
Methods
Animal husbandry
Mice were obtained from The Jackson Laboratory (Bar
Harbor, ME, USA). All animals were treated according to
the guidelines of the Association for Research in Vision
and Ophthalmology for use of animals in research. All
experimental protocols were approved by the Animal Care
and Use Committee of The Jackson Laboratory. The
DBA/2J (D2) mice were maintained on an NIH 31 diet
with a fat content of 6%. To avoid obesity, mice with a
C57BL/6J (B6) background were maintained on essentially
the same NIH 31 diet but with a 4% fat content. Our stud-
ies have shown that D2 IOP and other glaucoma phe-
notypes do not differ with this small dietary difference
(unpublished data). For all mice, the diet was provided ad
libitum, and water was acidified to pH 2.8–3.2. Mice were
housed in cages containing white-pine bedding and cov-
ered with polyester filters. The environment was kept at
21°C with a 14-hour light: 10-hour dark cycle.
Generation of strains
Mice with a perforin null allele (B6-Prf1tm1Sdz/J) (stock #
2407) were obtained from The Jackson Laboratory and
crossed to a congenic B6.D2-GpnmbR150X Tyrp1b strain[31] to produce mutants that were homozygous for all
three mutations (B6.Cg-Prf1tm1SdzTyrp1b GpnmbR150X/
Sj), referred to as the perforin mutant. In addition, mice
carrying IL2 receptor gamma chain null mutation (B6-
Il2rgtm1Wjl/J) were obtained from the Jackson Laboratory
and crossed to the B6.D2-GpnmbR150X Tyrp1b strain to
generate B6.Cg- Il2rgtm1Wjl Tyrp1b GpnmbR150X/Sj mice,
referred to as the Il2rg mutant. The Klrd1 (CD94) muta-
tion in D2 mice was determined to have occurred between
1984 and 1989. The sdy mutation alters coat color and oc-
curred in D2 mice in 1983. The DBA/2J-Dtnbp1sdy/J strain
(D2-sdy) was separated from the main D2 colony. Geno-
typing a D2-sdy colony for Klrd1 revealed that these mice
had an original wild-type allele. To develop the Klrd1+/+
strain, D2-sdy was crossed to modern D2 mice for three
generations. Congenic D2 Klrd1+/− mice were intercrossed
to produce Klrd1+/+, Klrd1+/−, and Klrd1−/− littermates.
All three genotypes were housed together and analyzed
simultaneously.
Flow cytometry
Peripheral blood mononuclear cells were stained with
monoclonal antibodies against CD94 and NKG2A/B/C
(The Jackson Laboratory Flow Cytometry Service). Label-
ing was assessed by multicolor flow cytometry (FACScan™
or FACScalibur®; BD Biosciences) and analyzed using the
CellQuest 3.3 data reduction system (BD Biosciences).
Assay for Anterior Chamber Associated Immune
Deviation (ACAID)
Peritoneal Exudate Cells (PECs) obtained 3 days after i.p.
injection of mice with 2 ml of 3% thioglycollate solution
(Sigma Chemical Co., St. Louis, MO) were cultured
overnight in serum free medium with ovalbumin (OVA)
antigen (7 mg/ml) in the presence or absence of TGFβ2
(5 ng/ml). Cells were then harvested and washed three
times with cultured medium to remove excess TGFβ2
and non-adherent cells. Adherent cells that typically
contain >90% F4/80+ and >99% CD11b + cells [38]
served as antigen presenting cells (APCs). These cells
(2–5 x 103/mouse) were infused i.v. in recipients
immunized s.c. 7 days earlier with 50 μg OVA in
Complete Freund’s Adjuvant. A week later these mice
received intradermal inoculation of OVA (200 μg/20 μl)
in their right ear pinnae while left ears served as un-
treated controls. Thickness of both ears was measured
immediately before and at 24 hr interval after the OVA
injection using a micrometer (Mitutoyo, MTI Corp.,
Paramus, NJ). The measurements were performed in
triplicates. Delayed type hypersensitivity (DTH) was
measured as a change in ear swelling ([24-hr measure-
ment – 0-hr measurement in the experimental right
ear] – [24-hr measurement – 0-hr measurement in
the control left ear]). Suppression of DTH in the
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the DTH response detected in a group receiving untreated
APCs. A two-tailed Student’s t-test was used to assess
significance.
Clinical examination
Eyes were examined with a slit-lamp biomicroscope and
photographed with a 40× objective lens. Assessment of
iris disease was determined by indices of iris atrophy
and dispersed pigment following previously described cri-
teria [22]. Transillumination defects were also measured
(transillumination is an assay of iris disease whereby
reflected light passing through depigmented areas of iris
tissue are visualized as reddish light). Examination of at
least 20 mice of each genotype at 3, 6 and 9 months of
age, and at the time of harvest at 12 months, was per-
formed. Additionally, smaller groups of mice (10–20 of
each genotype) were analyzed every month between 3
and 12 month of age.
IOP measurement
IOP was measured using the microneedle method as
previously described in detail [39]. All cohorts included
male and female mice. B6 mice were interspersed with
experimental mice during all experiments as a methodo-
logical control to ensure proper equipment calibration and
performance. Analysis of Variance (ANOVA) was used to
test significance.
Optic nerve assessment
The majority of optic nerves were collected from mice
within 48 hours of IOP measurement. Samples from both
males and females, as well as left and right nerves were
used for analysis. Optic nerves were dissected, processed,
embedded in plastic, sectioned and stained with paraphe-
nylenediamine (PPD) as previously described. PPD stains
myelin sheaths of all axons and stains the axoplasm of sick
or dying axons darkly. Stained sections were compared
using a previously described qualitative grading [40].
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